Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B64b339de2a83d83b59d5742b99ae3f95> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B64b339de2a83d83b59d5742b99ae3f95 NCIT_P378 "NCI" @default.
- B64b339de2a83d83b59d5742b99ae3f95 type Axiom @default.
- B64b339de2a83d83b59d5742b99ae3f95 annotatedProperty IAO_0000115 @default.
- B64b339de2a83d83b59d5742b99ae3f95 annotatedSource NCIT_C173857 @default.
- B64b339de2a83d83b59d5742b99ae3f95 annotatedTarget "A fixed combination of atazanavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, and ritonavir, a cytochrome P450 3A4 (CYP3A4) inhibitor, that may be used to treat HIV-1 infection. Upon oral administration of atazanavir/ritonavir, atazanavir selectively binds to the active site of HIV-1 protease and inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions. Ritonavir inhibits CYP3A4, thereby limiting the metabolism of atazanavir, which is a CYP3A4 substrate, and increasing its systemic exposure. This leads to an increased concentration and half-life of atazanavir as compared to the administration of atazanavir without ritonavir." @default.